Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The impact of oral anticoagulant therapy, factor VIII level and quality offactor V-deficient plasma on three commercial methods for activated protein C resistance
Autore:
Chitolie, A; Lawrie, AS; Mackie, IJ; Harrison, P; Machin, SJ;
Indirizzi:
Univ Coll London Hosp, Dept Haematol, London, England Univ Coll London Hosp London England sp, Dept Haematol, London, England
Titolo Testata:
BLOOD COAGULATION & FIBRINOLYSIS
fascicolo: 3, volume: 12, anno: 2001,
pagine: 179 - 186
SICI:
0957-5235(200104)12:3<179:TIOOAT>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
APC-RESISTANCE; VENOUS THROMBOSIS; LEIDEN MUTATION; TESTS; ASSAY; GENE; CONTRACEPTIVES; THROMBOPHILIA; SPECIFICITY; COFACTOR;
Keywords:
activated protein C resistance; FV : Q(506); factor V deficient plasma; factor VIII; activated protein C; protein C activator; amidolytic assay;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Chitolie, A Univ Coll London, Haemostasis Res Unit, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England Univ Coll London 98 Chenies Mews LondonEngland WC1E 6HX land
Citazione:
A. Chitolie et al., "The impact of oral anticoagulant therapy, factor VIII level and quality offactor V-deficient plasma on three commercial methods for activated protein C resistance", BL COAG FIB, 12(3), 2001, pp. 179-186

Abstract

Several methods are now available for the laboratory assessment of activated protein C resistance (APCR). In this study, we evaluated two activated partial thromboplastin time-based assays [Coatest(R) activated protein C (APC) and Diagen protein C activator (PCA)I, with and without predilution of test plasma in factor V-deficient plasma (FVdp) and an amidolytic assay (Immuno Ltd, Vienna, Austria). Testing plasmas from normal volunteers who had received 1-deamino-8-D-arginine vasopressin (DDAVP) also assessed the effectof elevated factor VIII on APCR. In the unmodified clotting tests, the Coatest kit gave overlapping results for normal and heterozygous FV:Q(506) samples; some FV:Q(506) samples on oral anticoagulant therapy (OAT) were misclassified as normal, and some normal samples with high factor VIII levels would be classified as APC resistant. The unmodified Diagen kit correctly classified these three types of sample, but had the disadvantage that prolonged PCA clotting times gave serious problems with instrument end-point detection. Both kits modified by diluting the samples in FVdp correctly classified all the samples, as well as samples from patients with lupus anticoagulant (LA) and patients receiving heparin. The Immunochrom kit correctly classified the normal and FV:Q506 samples, but would have misclassified most normal persons on OAT as well as some patients with LA or receiving heparin therapy as APC resistant. Blood Coagul Fibrinolysis 12:179-186 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 16:49:45